The American Journal of Managed Care
This supplement to contains information on atypical antipsychotics and their cost effectiveness in the treatment of schizophrenia and bipolar disease.
Faculty
David J. Harrison, PhDSenior Manager
Pfizer Inc
Senior Director
New York, NY
Amie T. Joyce, MPH
PharMetrics, Inc
Medical Director
New York, NY
Michael B. Lustik, MS
Science Applications International Corporation
Director
New York, NY
Daniel A. Ollendorf, MPH
Analytic & Consulting Services
Watertown, MA
George M. Simpson, MD
Department of Psychiatry and the Behavioral Sciences
Los Angeles, CA
Richard C. Surles, PhD
Comprehensive NeuroScience, Inc
Senior Statistician
Reston, VA
Disclosure Statement
The American Journal of Managed Care
It is the policy of to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.
The following participants have declared the following affiliations with corporate organizations:
Robin P. Hertz, PhD
Employee:
Antony D. Loebel, MD
Employee:
Margaret McDonald, PhD
Employee:
George M. Simpson, MD
Consultant:
Research Support:
Richard C. Surles, PhD
Adviser:
The American Journal of Managed Care,
Signed disclosures are on file at the offices of Jamesburg, New Jersey.
This supplement was funded by Pfizer Inc.
Acknowledgments
We would like to thank Laura Brasseur and Debbie Godfrey for their contributions to this supplement.
The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.